Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blind placebo-controlled moscow study

Kalinchenko S.Y. ¹ , Tishova Y.A. ¹ , Mskhalaya G.J. ¹ , Gooren L.J. ¹ , Giltay E.J. ¹ , Saad F. ¹

2

English

Published

185

2011

C reactive protein; cholesterol; glucose; high density lipoprotein cholesterol; insulin; interleukin 10; interleukin 1beta; interleukin 6; leptin; low density lipoprotein cholesterol; placebo; testosterone undecanoate; triacylglycerol; tumor necrosis factor alpha; adult; aged; androgen therapy; body mass; body weight; disease association; double blind procedure; drug efficacy; human; hypogonadism; inflammation; major clinical study; male; metabolic syndrome X; note; outpatient department; phase 3 clinical trial; priority journal; randomized controlled trial; Russian Federation; testosterone blood level; therapy effect; treatment duration; waist circumference